Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Semaglutide may lower Alzheimer's risk in type 2 diabetes patients

Researchers at the Case Western Reserve School of Medicine have found that, when compared to seven other anti-diabetic drugs, semaglutide, a popular diabetes and weight-loss drug, may lower the risk of Alzheimer's disease in people with type 2 diabetes (T2D).

24 Oct 2024

PIONEER software breaks down barriers in protein-protein interaction research

Scientists from Cleveland Clinic and Cornell University have designed a publicly-available software and web database to break down barriers to identifying key protein-protein interactions to treat with medication.

24 Oct 2024

Researchers create mini-brains to study autism and test new treatments

Using stem cells generated from patients with a rare and severe form of autism spectrum disorder and intellectual disability, Scripps Research scientists have grown personalized "mini-brains" (or organoids) to study the disorder in new detail.

23 Oct 2024

Southwest Research Institute breaks ground on new clinical supply facility

Southwest Research Institute broke ground today on a new 21,000-square-foot Clinical Supply Facility to support government and industry clients with integrated pharmaceutical and bioengineering research and development.

23 Oct 2024

Human midbrain organoids: A promising tool in the fight against Parkinson's disease

Advancements in organoid technology are crucial for Parkinson's disease research, providing human-relevant models for studying disease and testing therapies.

23 Oct 2024

New drug shows promise for motor neurone disease treatment

A pioneering study published in the International Journal of Molecular Sciences by researchers at Durham University has revealed promising results for a new treatment targeting motor neurone disease (MND).

22 Oct 2024

Axol Bioscience acquires Phenocell to advance human disease models

Axol Bioscience Ltd. (Axol), a leading induced pluripotent stem cell (iPSC) technology provider for drug discovery, today announced it has fully acquired Phenocell SAS, a pioneer in iPSC-based products and bioassays for skin and retinal disorders.

From Axol Bioscience Ltd 22 Oct 2024

Scientists map the genetic landscape of drug resistance in cancers

All cancer mutations that cause drug resistance fall into one of four categories. New research has detailed each type, helping to uncover targets for drug development and identify potential effective second-line therapies.

18 Oct 2024

Ubiquigent partners with Alleo Labs to advance DUB-targeting therapies

Ubiquigent Limited (“Ubiquigent”), a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, today announced a strategic partnership with Alleo Labs Corp. (“Alleo”), a pioneer in using artificial intelligence (AI) to develop new therapeutics for neurological diseases.

18 Oct 2024

Sapio Sciences enhances lab informatics platform with new immunogenicity bioanalysis features

Sapio Sciences, the science-aware™ lab informatics platform, today announced the addition of new immunogenicity bioanalysis features to its industry-leading lab informatics platform.

18 Oct 2024

Revealing the hidden role of blood leaks in Alzheimer’s and MS

The question of what causes complex neurological diseases such as Alzheimer's or multiple sclerosis continues to confound scientists and doctors, with the unknowns standing in the way of early diagnoses and effective treatments.

18 Oct 2024

University of Miami invests $30 million in neuroscience and aging research

Demonstrating its commitment to excellence as a member of the Association of American Universities and number one in the state for National Institutes of Health (NIH) funding, the University of Miami has pledged to invest more than $30 million to bolster basic science research that will target neuroscience and aging, some of the most complex conditions confronting the United States population, including in South Florida.

17 Oct 2024

Brazil-Italy joint lab focuses on Alzheimer’s drug development

A self-proclaimed Brazil-Italy collaboration enthusiast, researcher Laura Bolognesi created the B2AlzD2 Joint Lab at the Department of Pharmacy and Biotechnology of the Università di Bologna (UNIBO), the first Brazil-Bologna joint laboratory dedicated to the development of new drugs for the treatment of Alzheimer's disease.

17 Oct 2024

New synthesis technology promises faster production of mRNA vaccines

In an era where viral outbreaks can escalate into global pandemics with alarming speed, the ability to quickly develop new vaccines has become crucial.

17 Oct 2024

Tissue chips help translate respiratory disease research into clinical applications

Scientists are developing advanced tools to understand and treat neurological symptoms such as brain fog associated with respiratory diseases like influenza.

17 Oct 2024

FDA strengthens AI regulation to ensure patient safety and innovation in healthcare

The FDA is adapting regulations to manage AI’s rapid development in healthcare, focusing on patient safety and the life cycle of AI tools. This review emphasizes the need for continuous monitoring to ensure AI performs effectively in clinical settings.

16 Oct 2024